Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when INCY files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsIncyte Q2 revenue up 38% to $1.67B on $246M Opzelura CMS settlement and strong product growth
Filed July 28, 2026 · Period ending July 28, 2026 · ~2 min read
Key Changes
-
high
Q2 2026 total revenue $1.67B (+38% YoY) and net sales $1.49B (+40% YoY), driven by increased demand across marketed products and a one-time $246M non-cash benefit from Opzelura CMS settlement reversing prior Medicaid rebate accruals.
Exhibit 99.1 view on EDGAR → -
high
Settled CMS litigation on Opzelura Medicaid rebates; CMS will not treat Opzelura as a Jakafi line extension. One-time $246M benefit in Q2 plus improved gross-to-net profile yields $300-$310M total estimated incremental impact on 2026 Opzelura net sales.
Exhibit 99.1 view on EDGAR → -
high
Completed acquisition of Vega Therapeutics for $1.25B upfront in July 2026, adding Phase 3 von Willebrand disease candidate latarcibart to pipeline. Star Therapeutics eligible for up to $750M in sales milestones; acquisition will result in ~$1.27B IPR&D expense in Q3 2026.
Exhibit 99.1 view on EDGAR → -
high
Raised full year 2026 total net sales guidance to $5,130-$5,260M (from $4,770-$4,940M), Opzelura guidance to $1,050-$1,100M (from $750-$790M), and Hematology/Oncology guidance to $860-$890M (from $800-$880M), reflecting CMS settlement and strong product performance.
Exhibit 99.1 view on EDGAR → -
high
Phase 3 frontMIND trial for Monjuvi/Minjuvi in first-line DLBCL showed statistically significant PFS improvement; global regulatory submissions accepted in Q2 2026 with potential U.S. approval and launch anticipated in Q1 2027.
Exhibit 99.1 view on EDGAR →
Summary
Incyte reported strong Q2 2026 results with total revenue of $1.67 billion, up 38% year-over-year, driven by robust underlying product demand and a significant one-time benefit. The company settled litigation with CMS over Medicaid rebate treatment of Opzelura, its topical ruxolitinib cream for dermatologic conditions.
Under the agreement, CMS will not apply line extension regulations that would have tied Opzelura's rebates to Jakafi, Incyte's oral ruxolitinib hematology drug. This resulted in a $246 million non-cash benefit in Q2 from reversing previously accrued liabilities, with total estimated incremental impact on 2026 Opzelura net sales of $300-$310 million including improved future gross-to-net margins.
The settlement removes a material pricing overhang and validates Incyte's position that the two products serve distinct patient populations. Incyte also completed its $1.25 billion acquisition of Vega Therapeutics in July, adding latarcibart—a Phase 3 monoclonal antibody for von Willebrand disease—to its late-stage pipeline. The deal includes up to $750 million in sales milestones and will generate an approximately $1.27 billion IPR&D expense in Q3 2026. Separately, the company's Phase 3 frontMIND trial for Monjuvi/Minjuvi in first-line DLBCL met its primary endpoint with statistically significant progression-free survival improvement; regulatory submissions were accepted in Q2 with potential U.S. approval in Q1 2027. Management raised full-year 2026 net sales guidance to $5,130-$5,260 million (from $4,770-$4,940 million), reflecting the CMS settlement impact and continued strength in Hematology/Oncology products including Niktimvo, Monjuvi/Minjuvi, and Zynyz.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Incyte announced Q2 2026 financial results via press release.
Added in current filing · verify on EDGAR →
On July 28, 2026, Incyte Corporation issued a press release announcing financial results for its second fiscal quarter ended June 30, 2026.
Incyte disclosed its second quarter 2026 financial results through a press release. The 8-K does not include the actual financial figures in the body text; those details are contained in the attached Exhibit 99.1 press release, which was not provided for analysis.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 29, 2026 · How we verify